Related Experiment Video

Updated: Apr 17, 2026

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
10:52

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

Published on: April 7, 2014

18.8K

Corneal neovascularization and contemporary antiangiogenic therapeutics

Chih-Chien Hsu1, Hua-Ming Chang2, Tai-Chi Lin1

  • 1Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.

Journal of the Chinese Medical Association : JCMA
|February 18, 2015
PubMed

Insights

Corneal neovascularization (NV) causes vision loss and current treatments are often ineffective for large vessels. Research explores new therapeutic targets and inhibitors to improve treatment outcomes for this condition.

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Regenerative Medicine

Background:

  • Corneal neovascularization (NV) involves blood vessel growth into the cornea, impairing vision.
  • Current treatments like steroids, laser photocoagulation, and bevacizumab injections show limitations, particularly for large, recalcitrant vessels prone to recanalization.

Purpose of the Study:

  • To review the pathogenesis of corneal NV.
  • To highlight established animal models for corneal NV research.
  • To survey recent therapeutic targets, inhibitors, and immunosuppressants for corneal NV.

Main Methods:

  • Literature review of corneal neovascularization pathogenesis.
  • Analysis of existing animal models: alkali-induced and suture-induced.
  • Survey of therapeutic strategies including growth factor inhibitors and immunosuppressants.

Main Results:

  • Corneal NV is a significant cause of visual impairment with challenging treatment scenarios.
  • Alkali-induced and suture-induced models are key tools for studying corneal NV.
  • Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) are identified as crucial targets.

Conclusions:

  • Effective treatment of corneal NV, especially large vessels, remains a clinical challenge.
  • Animal models are essential for advancing research into corneal NV.
  • Targeting VEGF, PDGF, and exploring novel immunosuppressants offer promising avenues for future therapies.
Keywords:
angiogenesisantiangiogenesiscorneal neovascularizationimmunosuppressantvascular endothelial growth factor

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Author Spotlight: Decoding Corneal Neovascularization with Alkali Burn Model for Future Therapeutic Strategies04:17

Author Spotlight: Decoding Corneal Neovascularization with Alkali Burn Model for Future Therapeutic Strategies

Published on: June 30, 2023

4.8K

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K